Clinical trial Mountaineer-03
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer(SGNTUC-029 - Mountaineer-03)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Seagen |
| EudraCT Identifier | 2021-002672-40 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05253651 |
| Last update |